Epidiolex (Cannabidiol) is a Schedule V Controlled Substance

Yesterday, the Drug Enforcement Administration announced that Epidiolex, which contains cannabidiol (CBD), a chemical constituent of the cannabis or marijuana plant is a Schedule V Controlled Substance, which is the least restrictive schedule of the Controlled Substance Act.

In June 2018, the Food and Drug Administration announced it approved Epidiolex (cannabidiol), for the treatment of seizures associated with Lennox-Gastaut Syndrome and Dravet Syndrome in patients two years and older.

Epidiolex is the first FDA-approved drug to contain a purified extract (i.e. CBD) from the cannabis plant.